Overview
Mabion is a European contract development and manufacturing organization (CDMO) specializing in biologics manufacturing, including drug substance manufacturing, analytics, and fill & finish processes. The company offers end-to-end development services from gene to vial, as well as cell line development and banking. Mabion collaborates with various pharmaceutical companies on projects such as the development of antibody-drug conjugates (ADCs) and analytical method development.
Stock quotes
- Open
- PLN 7.80
- High
- PLN 7.90
- Low
- PLN 7.64
- Volume
- 11.29K
- Avg. vol.
- 18.33K
- Market cap
- PLN 126.87M
- P/E ratio
- —
- EPS
- -PLN 3.50
- Shares outstanding
- 16.16M
- 52-week
- PLN 7.63 – 7.99
- Dividend yield
- —
- Dividend
- —
- Ex dividend date
- —
- ISIN
- PLMBION00016
- Exchange
- GPW Main Market
Quarterly results
| Period | Revenue | EBIT | Net profit |
|---|---|---|---|
| Q2 2026 | USD 881.42k | USD -3.73m | USD -4.03m |
| Q1 2026 | USD 1.23m | USD -2.48m | USD -2.63m |
| Q4 2025 | USD 1.43m | USD -5.06m | USD -5.32m |
| Q3 2025 | USD 1.03m | USD -2.69m | USD -2.70m |
Results for Q3 2026:Nov 17, 2026
News
Breakthrough in the treatment of Huntington’s disease
AAV gene therapy for Huntington's disease nears FDA and MHRA approval. AMT-130 is a drug delivered directly into the deep parts of the brain.
Jakub Knurek once again among the TOP 5 Future Leaders at the CPHI Pharma Awards
Jakub Knurek is a Future Leader in the Biopharmaceutical Industry. Our expert was a finalist in the 2026 CPHI Pharma Awards in this category.
Success of mRNA Cancer Vaccine
Personalized mRNA cancer vaccine reported positive clinical results in combination with pembrolizumab for patients with high-risk melanoma.
MabionCD20 development path in dialogue with the FDA
Connecting CMC, analytics and regulatory strategy. Turning biologics expertise into MabionCD20 development path.
Mabion receives the Responsible Entrepreneur Certificate
Mabion receives the Responsible Entrepreneur Certificate in recognition of our commitment to corporate social responsibility.
New ranibizumab biosimilar enters the market
Learn about the development of ranibizumab and its biosimilars in the treatment of ophthalmological diseases.
Industry
Bank accounts
Registered as a VAT taxpayer on 2007-06-01. Active
61 1090 1304 0000 0001 4958 5216- 02 1090 1304 0000 0001 3453 2945
02 1140 1108 0000 3129 5400 1001
Debt
No entries in the National Debtors Register (KRZ). No proceedings in KRZ
MSiG notices
| Publication date | Event | |
|---|---|---|
| Jan 15, 2025 | Bankruptcy notice | |
| Jan 22, 2020 | Bankruptcy sale | |
| Nov 2, 2018 | Bankruptcy notice | |
| Jun 7, 2010 | Shareholders' meeting convened | |
| Mar 26, 2010 | Shareholders' meeting convened |
Public aid
15 public aid cases recorded, with a total value of $19,962,995.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Jan 16, 2026 | De minimis aid (in accordance with Commission Regulation 2023/2831) | —— | Prezes Zakładu Ubezpieczeń Społecznych | |
| Dec 2, 2025 | De minimis aid (in accordance with Commission Regulation 2023/2831) | —— | Prezes Zakładu Ubezpieczeń Społecznych | |
| Dec 2, 2025 | De minimis aid (in accordance with Commission Regulation 2023/2831) | —— | Prezes Zakładu Ubezpieczeń Społecznych |
European Funds
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2021-09-18 | Opracowanie panelu metod analitycznych do charakterystyki immunogenności w badaniu klinicznym skierowanym do pacjentów cierpiących na reumatoidalne zapalenie stawów z wykorzystaniem rituximabu jako substancji leczniczej. | $538.4K$538,425 | Regionalny Program Operacyjny Województwa Łódzkiego na lata 2014-2020 | |
| 2017-08-01 | Rozwój leku biotechnologicznego poprzez opracowanie innowacyjnego przeciwciała monoklonalnego podklasy IgG1 o obniżonej zawartości niekorzystnych glikoform względem leku referencyjnego – skierowanego przeciwko EGFR | $7.4M$7,442,721 | Program Operacyjny Inteligentny Rozwój | |
| 2016-11-01 | Rozwój i skalowanie innowacyjnego procesu wytwarzania terapeutycznego, rekombinowanego przeciwciała monoklonalnego, w celu umożliwienia przemysłowego wdrożenia pierwszego polskiego leku biotechnologicznego do terapii onkologicznych oraz autoimmunologicznych. | $6.8M$6,834,236 | Program Operacyjny Inteligentny Rozwój |
Tenders
No recorded participation in tenders.
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
 BDO | Integrated permit | Active |
Authorized Representatives
Manner of representation
The following are authorized to make declarations of will on behalf of the company: two members of the management board acting jointly or one member of the management board acting jointly with a commercial proxy.
Supervisory board
Beneficial owners
No beneficial owners recorded for the company Mabion.
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Polpharma BiologicsS.A. | $19,057,541.37 | polpharmabiologics.com | ||
| MPR Labssp. z o.o. | $833,714.20 | mpr-labs.com | ||
| BiottsS.A. | $372,115.60 | biotts.com | ||
| Medicofarma BiotechS.A. | $314,882.33 | medicofarmabiotech.pl | ||
| Nexbiosp. z o.o. | $186,582.40 | nexbio.pl | ||
| FcbiotechS.A. | $148,945.77 | fcbiotech.pl | ||
| ModicaP.S.A. | $103,400.72 | modica.bio | ||
| Jotachemsp. z o.o. | $6,512.58 | jotachem.pl | ||
| Fusiomicasp. z o.o. | $5,263.98 | fusiomica.com | ||
| MolecureS.A. | $10.77 | molecure.com |
Change history
| Date | Event | |
|---|---|---|
| 2022-11-29 | Share capital change (1,616,182.60 PLN → 1,616,232.60 PLN) | |
| 2022-04-20 | Share capital change (1,616,132.60 PLN → 1,616,182.60 PLN) | |
| 2021-04-02 | Share capital change (1,373,027.20 PLN → 1,616,132.60 PLN) | |
| 2020-06-18 | Share capital change (1,372,077.20 PLN → 1,373,027.20 PLN) | |
| 2018-04-30 | Share capital change (1,180,000.00 PLN → 1,372,077.20 PLN) |
FAQ
Last updated: 2026-08-10